Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Vascular Biogen. Ord (VBLT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 202,164
  • Shares Outstanding, K 29,730
  • Annual Sales, $ 0 K
  • Annual Income, $ -16,000 K
  • 36-Month Beta -3.00
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.23

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.27 +6.86%
on 12/07/17
9.05 -25.97%
on 11/16/17
-0.98 (-12.70%)
since 11/15/17
3-Month
5.20 +28.85%
on 09/18/17
9.05 -25.97%
on 11/16/17
+1.45 (+27.62%)
since 09/15/17
52-Week
3.90 +71.79%
on 08/04/17
9.05 -25.97%
on 11/16/17
+2.20 (+48.89%)
since 12/15/16

Most Recent Stories

More News
VBL Therapeutics Prices 2.5 Million Ordinary Share Offering

VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced the pricing of...

VBLT : 6.70 (-1.47%)
VBL Therapeutics Announces Proposed Public Offering of 2.5 Million Shares of Ordinary Shares

VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it is offering...

VBLT : 6.70 (-1.47%)
VBL Therapeutics Announces Third Quarter 2017 Financial Results

Conference Call and Webcast at 8:30am Eastern Time Today

VBLT : 6.70 (-1.47%)
Vascular Biogenics Ltd. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 14, 2017 / Vascular Biogenics Ltd. (NASDAQ: VBLT) will be discussing their earnings results in their Q3 Earnings Call to be held on November 14, 2017 at 8:30 AM Eastern...

VBLT : 6.70 (-1.47%)
VBL Therapeutics to Present at the 22nd Annual Scientific Meeting of the Society for Neuro-Oncology (SNO) on November 18

VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announces that Andrew Brenner,...

VBLT : 6.70 (-1.47%)
Clinical Studies Elevating Biotech Drug Development to New Levels for Unmet Medical Needs

PALM BEACH, Florida, November 7, 2017 /PRNewswire/ --

CARA : 12.71 (+0.71%)
CTXR : 4.70 (+0.21%)
ONCS : 1.59 (-7.02%)
TXMD : 6.62 (+2.16%)
VBLT : 6.70 (-1.47%)
Clinical Studies Elevating Biotech Drug Development to New Levels for Unmet Medical Needs

Commitment to bring new drug developments to the market through highly regarded and respected clinical research and studies are of a continued result of ongoing collaborations with academic and medical...

CARA : 12.71 (+0.71%)
CTXR : 4.70 (+0.21%)
ONCS : 1.59 (-7.02%)
VBLT : 6.70 (-1.47%)
TXMD : 6.62 (+2.16%)
VBL Therapeutics and NanoCarrier Co., Ltd. Sign Exclusive Agreement for VB-111 in Japan

Agreement includes $15 million up front, potential milestones payments of more than $100 million, as well as tiered high-teen royalties

VBLT : 6.70 (-1.47%)
VBL Therapeutics Celebrates Opening of its New Gene Therapy Manufacturing Plant and Company Headquarters

VBL Therapeutics (NASDAQ:VBLT) announced today the opening of its new gene therapy manufacturing plant in Modiin, Israel. This plant will be the commercial facility for production of the Company's lead...

VBLT : 6.70 (-1.47%)
VBL Therapeutics Announces Orphan Drug Designation for VB-111 in Europe

New EMA orphan approval for Ovarian Cancer complements previously granted VB-111 orphan status for Glioblastoma in the US and Europe

VBLT : 6.70 (-1.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment...

See More

Key Turning Points

2nd Resistance Point 7.03
1st Resistance Point 6.87
Last Price 6.70
1st Support Level 6.57
2nd Support Level 6.43

See More

52-Week High 9.05
Fibonacci 61.8% 7.08
Last Price 6.70
Fibonacci 50% 6.48
Fibonacci 38.2% 5.87
52-Week Low 3.90

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.